Document is current
Any future updates will be listed below
-
Authors
Furusho, Taisuke https://orcid.org/0009-0001-5339-140X
Das, Ranjan https://orcid.org/0000-0002-7951-4121
Hakui, Hideyuki https://orcid.org/0000-0002-0335-3149
Sairavi, Anusha
Adachi, Kei https://orcid.org/0009-0008-4283-5424
Galbraith-Liss, Mia S. https://orcid.org/0009-0009-6013-5090
Rajagopal, Pratheppa https://orcid.org/0009-0000-7337-5776
Horikawa, Masahiro
Luo, Shuhua https://orcid.org/0009-0007-5608-7167
Li, Lena
Yamada, Kentaro https://orcid.org/0000-0001-5957-3389
Andeen, Nicole https://orcid.org/0000-0002-4882-6640
Dissen, Gregory A.
Nakai, Hiroyuki https://orcid.org/0000-0002-4213-3130
-
Funding
Funding for this research was provided by:
Otsuka Pharmaceutical (not applicable)
U.S. Department of Health & Human Services | National Institutes of Health (P51 OD011092)
National Science Foundation (ACI-1928147)
- License Information
-
More Information
Article History
Received: 17 January 2024
Accepted: 13 November 2024
First Online: 30 December 2024
Competing interests
: K.A. and H.N. receive a royalty of AAV-related technologies licensed by Takara Bio Inc. and Capsigen Inc. H.N. serves as a consultant for biotech companies, is a co-founder of Capsigen Inc., and holds shares of Capsigen Inc. and Sphere Gene Therapeutics. The remaining authors declare no competing interests.
